| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
|
Sweeney, Christopher J.
|
|
2009
|
66 |
2 |
p. 345-356
|
article
|
| 2 |
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
|
Cohen, Steven J.
|
|
2009
|
66 |
2 |
p. 287-294
|
article
|
| 3 |
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
|
Ishii, Yukimoto
|
|
2009
|
66 |
2 |
p. 333-343
|
article
|
| 4 |
Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
|
Greene, Daniel P.
|
|
2009
|
66 |
2 |
p. 265-267
|
article
|
| 5 |
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
|
Choi, Yun Jung
|
|
2009
|
66 |
2 |
p. 381-388
|
article
|
| 6 |
Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo
|
Ye, Xiaolei
|
|
2010
|
66 |
2 |
p. 277-285
|
article
|
| 7 |
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
|
Helsby, N. A.
|
|
2010
|
66 |
2 |
p. 405-407
|
article
|
| 8 |
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
|
Thompson, Karol L.
|
|
2009
|
66 |
2 |
p. 303-314
|
article
|
| 9 |
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase
|
Réti, Andrea
|
|
2009
|
66 |
2 |
p. 219-227
|
article
|
| 10 |
Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
|
Todorova, Valentina K.
|
|
2009
|
66 |
2 |
p. 315-323
|
article
|
| 11 |
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
|
Caponigro, F.
|
|
2009
|
66 |
2 |
p. 389-394
|
article
|
| 12 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
|
Buch-Hansen, Trine Zeeberg
|
|
2009
|
66 |
2 |
p. 295-301
|
article
|
| 13 |
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
|
Sym, Sun Jin
|
|
2009
|
66 |
2 |
p. 373-380
|
article
|
| 14 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents
|
Goteti, Kosalaram
|
|
2009
|
66 |
2 |
p. 245-254
|
article
|
| 15 |
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
|
Fujimoto-Ouchi, Kaori
|
|
2009
|
66 |
2 |
p. 269-276
|
article
|
| 16 |
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials
|
Nasti, G.
|
|
2010
|
66 |
2 |
p. 209-218
|
article
|
| 17 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
|
Houk, Brett E.
|
|
2009
|
66 |
2 |
p. 357-371
|
article
|
| 18 |
Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines
|
Horio, Yoshitsugu
|
|
2009
|
66 |
2 |
p. 237-243
|
article
|
| 19 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
|
Mitry, Emmanuel
|
|
2010
|
66 |
2 |
p. 395-403
|
article
|
| 20 |
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy
|
Katta, Anilkumar
|
|
2010
|
66 |
2 |
p. 409-412
|
article
|
| 21 |
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
|
Lee, Su Jin
|
|
2009
|
66 |
2 |
p. 229-235
|
article
|
| 22 |
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
|
Radujkovic, Aleksandar
|
|
2009
|
66 |
2 |
p. 255-264
|
article
|
| 23 |
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
|
Sookraj, Kelley A.
|
|
2010
|
66 |
2 |
p. 325-331
|
article
|
Journal description